KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Interest Expenses (2017 - 2025)

Biomarin Pharmaceutical's Interest Expenses history spans 16 years, with the latest figure at $2.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 7.8% year-over-year to $2.8 million, compared with a TTM value of $10.9 million through Dec 2025, down 13.95%, and an annual FY2025 reading of $10.9 million, down 13.95% over the prior year.
  • Interest Expenses for Q4 2025 was $2.8 million at Biomarin Pharmaceutical, up from $2.6 million in the prior quarter.
  • The five-year high for Interest Expenses was $6.1 million in Q4 2023, with the low at $2.6 million in Q4 2024.
  • Average Interest Expenses over 5 years is $3.6 million, with a median of $3.7 million recorded in 2023.
  • Year-over-year, Interest Expenses crashed 59.67% in 2021 and then soared 68.17% in 2023.
  • Tracing BMRN's Interest Expenses over 5 years: stood at $3.8 million in 2021, then dropped by 5.72% to $3.6 million in 2022, then surged by 68.17% to $6.1 million in 2023, then crashed by 57.74% to $2.6 million in 2024, then increased by 7.8% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Interest Expenses are $2.8 million (Q4 2025), $2.6 million (Q3 2025), and $2.7 million (Q2 2025).